Evidence map›Paper›PMID 31481612›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2019

Decreased humoral immunity to mumps in young adults immunized with MMR vaccine in childhood.

Mohammed Ata Ur Rasheed, Carole J Hickman, Marcia McGrew, Sun Bae Sowers, Sara Mercader, Amy Hopkins, Vickie Grimes, Tianwei Yu, Jens Wrammert, Mark J Mulligan and 5 more

Registry-linked trialAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00962819 (Persistence of Humoral and Cellular Immune Responses Following Age-appropriate Vaccination With the MMR Vaccine), which is not on this map. Cited by 42 papers.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00962819 completednot on this map

Persistence of Humoral and Cellular Immune Responses Following Age-appropriate Vaccination With the MMR Vaccine

TypeobservationalSponsorSri Edupuganti, MD MPHRan2010 to 2012Enrolled74ConditionsMeasles, Mumps, RubellaArmsMMR vaccine
3 · Its place in the literature

Who cites it

42 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Observational
  16. Structure-based design of glycoprotein subunit vaccines for mumps.Proceedings of the National Academy of Sciences of the United States of America · 2024
    Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Mohammed Ata Ur RasheedEmory Vaccine Center, Emory University School of Medicine, Atlanta, GA 30322.
Carole J HickmanDivision of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30329.
Marcia McGrewDivision of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30329.
Sun Bae SowersDivision of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30329.
Sara MercaderDivision of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30329.
Amy HopkinsDivision of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30329.
Vickie GrimesHope Clinic of the Emory Vaccine Center, Department of Medicine, Division of Infectious Diseases, Emory University School of Medicine, Atlanta, GA 30030.
Tianwei YuDepartment of Biostatistics and Bioinformatics, Emory University, Atlanta, GA 30322.
Jens WrammertEmory Vaccine Center, Emory University School of Medicine, Atlanta, GA 30322.
Mark J MulliganHope Clinic of the Emory Vaccine Center, Department of Medicine, Division of Infectious Diseases, Emory University School of Medicine, Atlanta, GA 30030.
William J BelliniDivision of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30329.
Paul A RotaDivision of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30329.
Walter A OrensteinEmory Vaccine Center, Emory University School of Medicine, Atlanta, GA 30322.
Rafi AhmedEmory Vaccine Center, Emory University School of Medicine, Atlanta, GA 30322; rahmed@emory.edu sedupug@emory.edu.
Srilatha EdupugantiHope Clinic of the Emory Vaccine Center, Department of Medicine, Division of Infectious Diseases, Emory University School of Medicine, Atlanta, GA 30030; rahmed@emory.edu sedupug@emory.edu.

Funding

ALABAMA/ZAMBIA HIV VACCINE CLINICAL TRIALS UNIT (HVTU)U01AI047996 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI GOEPFERT, PAUL A. · 2000 to 2006
$8.4M
NIAID NIH HHS U01 AI047996
6 · The paper itself

Abstract

In the past decade, multiple mumps outbreaks have occurred in the United States, primarily in close-contact, high-density settings such as colleges, with a high attack rate among young adults, many of whom had the recommended 2 doses of mumps-measles-rubella (MMR) vaccine. Waning humoral immunity and the circulation of divergent wild-type mumps strains have been proposed as contributing factors to mumps resurgence. Blood samples from 71 healthy 18- to 23-year-old college students living in a non-outbreak area were assayed for antibodies and memory B cells (MBCs) to mumps, measles, and rubella. Seroprevalence rates of mumps, measles, and rubella determined by IgG enzyme-linked immunosorbent assay (ELISA) were 93, 93, and 100%, respectively. The index standard ratio indicated that the concentration of IgG was significantly lower for mumps than rubella. High IgG avidity to mumps Enders strain was detected in sera of 59/71 participants who had sufficient IgG levels. The frequency of circulating mumps-specific MBCs was 5 to 10 times lower than measles and rubella, and 10% of the participants had no detectable MBCs to mumps. Geometric mean neutralizing antibody titers (GMTs) by plaque reduction neutralization to the predominant circulating wild-type mumps strain (genotype G) were 6-fold lower than the GMTs against the Jeryl Lynn vaccine strain (genotype A). The majority of the participants (80%) received their second MMR vaccine ≥10 years prior to study participation. Additional efforts are needed to fully characterize B and T cell immune responses to mumps vaccine and to develop strategies to improve the quality and durability of vaccine-induced immunity.

Indexed as

AdolescentAdultAntibodies, NeutralizingAntibodies, ViralChildChild, PreschoolFemaleHumansImmunity, HumoralImmunizationImmunoglobulin GInfantMaleMeasles-Mumps-Rubella VaccineMumpsMumps virusAntibodies, NeutralizingAntibodies, ViralImmunoglobulin GMeasles-Mumps-Rubella VaccineIgG ELISAmemory B cells (MBCs)MMR vaccinemumps, measles, rubellaplaque reduction neutralization titers

Identifiers

PMID31481612
PMCPMC6754597

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.